GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » Piotroski F-Score

Sana Biotechnology (Sana Biotechnology) Piotroski F-Score : 1 (As of Apr. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sana Biotechnology Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sana Biotechnology has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Sana Biotechnology's Piotroski F-Score or its related term are showing as below:

SANA' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 1   Max: 3
Current: 1

During the past 6 years, the highest Piotroski F-Score of Sana Biotechnology was 3. The lowest was 1. And the median was 1.


Sana Biotechnology Piotroski F-Score Historical Data

The historical data trend for Sana Biotechnology's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology Piotroski F-Score Chart

Sana Biotechnology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 3.00 1.00 1.00

Sana Biotechnology Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 1.00 - 1.00

Competitive Comparison of Sana Biotechnology's Piotroski F-Score

For the Biotechnology subindustry, Sana Biotechnology's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sana Biotechnology's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sana Biotechnology's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sana Biotechnology's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -82.123 + -113.999 + 0.984 + -88.117 = $-283.26 Mil.
Cash Flow from Operations was -79.272 + -58.801 + -63.55 + -51.959 = $-253.58 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(822.72 + 746.928 + 707.147 + 631.44 + 565.299) / 5 = $694.7068 Mil.
Total Assets at the begining of this year (Dec22) was $822.72 Mil.
Long-Term Debt & Capital Lease Obligation was $90.90 Mil.
Total Current Assets was $213.52 Mil.
Total Current Liabilities was $64.49 Mil.
Net Income was -31.448 + -72.465 + -85.12 + -80.443 = $-269.48 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1129.407 + 1047.613 + 971.089 + 898.102 + 822.72) / 5 = $973.7862 Mil.
Total Assets at the begining of last year (Dec21) was $1,129.41 Mil.
Long-Term Debt & Capital Lease Obligation was $95.86 Mil.
Total Current Assets was $444.44 Mil.
Total Current Liabilities was $111.50 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sana Biotechnology's current Net Income (TTM) was -283.26. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sana Biotechnology's current Cash Flow from Operations (TTM) was -253.58. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-283.255/822.72
=-0.34429089

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-269.476/1129.407
=-0.23859955

Sana Biotechnology's return on assets of this year was -0.34429089. Sana Biotechnology's return on assets of last year was -0.23859955. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sana Biotechnology's current Net Income (TTM) was -283.26. Sana Biotechnology's current Cash Flow from Operations (TTM) was -253.58. ==> -253.58 > -283.26 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=90.901/694.7068
=0.13084801

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=95.86/973.7862
=0.0984405

Sana Biotechnology's gearing of this year was 0.13084801. Sana Biotechnology's gearing of last year was 0.0984405. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=213.515/64.487
=3.31097741

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=444.437/111.504
=3.98583907

Sana Biotechnology's current ratio of this year was 3.31097741. Sana Biotechnology's current ratio of last year was 3.98583907. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sana Biotechnology's number of shares in issue this year was 197.349. Sana Biotechnology's number of shares in issue last year was 190.441. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Sana Biotechnology's gross margin of this year was . Sana Biotechnology's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0/822.72
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/1129.407
=0

Sana Biotechnology's asset turnover of this year was 0. Sana Biotechnology's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sana Biotechnology has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Sana Biotechnology  (NAS:SANA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sana Biotechnology Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sana Biotechnology (Sana Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.
Executives
Christian Hordo officer: SVP, Chief Business Officer C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams officer: EVP & President, R&D C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy officer: EVP & General Counsel C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
James J. Macdonald officer: See Remarks C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal officer: See Remarks 60 LEVERONI COURT, NOVATO CA 94949
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship V Venturelabs Rx Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Venturelabs V Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sana Biotechnology (Sana Biotechnology) Headlines

From GuruFocus

Sana Biotechnology to Host Research & Development Day

By sperokesalga sperokesalga 04-24-2023

Sana Biotechnology to Present at June 2023 Investor Conferences

By sperokesalga sperokesalga 05-31-2023